1 **Consideration of within-patient diversity highlights transmission pathways and**

2 **antimicrobial resistance gene variability in vancomycin resistant *Enterococcus faecium***

3

4 **Martin P McHugh,[1,2]* Kerry A Pettigrew,[1] Surabhi Taori,[2] Thomas J Evans,[3] Alistair**

5 **Leanord,[3,4] Stephen H Gillespie,[1] Kate E Templeton,[2] Matthew TG Holden[1]**

6

7 [1]School of Medicine, University of St Andrews, St Andrews, UK

8 [2]Medical Microbiology, Department of Laboratory Medicine, Royal Infirmary of Edinburgh,

9 Edinburgh, UK

10 [3]School of Infection and Immunity, University of Glasgow, Glasgow, UK

11 [4]Scottish Microbiology Reference Laboratories, Glasgow, UK

12

13 *Corresponding author: Martin McHugh mpm20@st-andrews.ac.uk

14

15

16 **ABSTRACT**

17 Whole genome sequencing is increasingly applied to healthcare-associated vancomycin

18 resistant *Enterococcus faecium* (VREfm) outbreak investigations using single bacterial colonies

19 from individual patients. However, within-patient diversity could complicate transmission

20 resolution. We sequenced 14 colonies from VREfm positive rectal swabs over a 1-month period

21 on a haematology unit. In total, 224 isolates from 11 patients were sequenced. Carriage of 2-3

22 sequence types was detected in 27% of patients. Presence of antimicrobial resistance genes

23 and plasmids was variable within isolates from the same patient and sequence type. We

24 identified two dominant sequence types (ST80 and ST1424), with two putative transmission

25 clusters of two patients within ST80, and a single cluster of six patients within ST1424. We

found transmission resolution was impaired using fewer than 14 colonies, and therefore there is

a need to capture and consider VREfm within-patient diversity to ensure accurate resolution of

transmission networks.

INTRODUCTION

Enterococcus faecium is a leading nosocomial pathogen causing opportunistic infections mostly

in immunocompromised hosts. Antimicrobial resistance is a key concern, particularly against

front-line anti Gram-positive agents amoxicillin and vancomycin (1). Vancomycin resistant *E.*

faecium (VREfm) infections cause significant issues due to increased length of stay, cost an

estimated USD200 (GBP ~167) per case per day, and confer mortality of 23-47% (2–7). In

2020, vancomycin resistance of 45.6% was reported among all *E. faecium* bloodstream isolates

in Scotland, among the highest rates in Europe (8).

VREfm does not cause symptomatic gastrointestinal disease but asymptomatic intestinal

carriage is common. In healthcare settings, this can increase the risk of shedding into the

environment and transfer to other patients or staff, hence challenging efforts to limit the

incidence of nosocomial infections in high-risk settings (9). Whole genome sequencing is

increasingly applied to investigate transmission networks and identify control measures (10,11).

Most whole genome sequencing (WGS) based analyses of bacterial outbreaks, however, rely

on analysing single colony picks from clinical samples making the assumption that this

represents the entire infecting or colonizing population within individual patients (12). However,

it is increasingly recognised that within-patient diversity of bacterial populations can be

significant from a clinical and infection prevention control point of view, and can influence

transmission network resolution (13–19). Several studies have identified that individual patients

can carry multiple strains of *E. faecium* concurrently, but few have applied this to transmission

resolution (20–24).

In this study we aimed to identify within-patient diversity of VREfm from rectal screening

swabs and determine how this impacts transmission inference in a 1-month snapshot on a

haematology unit. We designed a sampling strategy to reliably detect within-patient diversity,

and supplemented short read and long read sequencing to generate high-quality reference

genomes to identify genomic variants in the isolate collection.

RESULTS

Epidemiological Context

This study was performed over a single month in 2017 on an 18-bed unit for patients

undergoing management of haematological malignancies. The unit is split into two wards (A and

B). Due to the high risk of invasive infection in this patient group, VREfm rectal screening was

performed on all new febrile admissions and any inpatients with febrile episodes to inform

patient placement and antimicrobial administration. Given the short study timeframe there was

significant overlap between patient stays with some patients moving between the two study

wards or to other wards in the hospital (Figure 1). There was a policy in place for patients to be

cohorted or placed in side rooms based on known colonisation or infection with high risk

pathogens (including *Candida auris*, *Clostridioides difficile*, methicillin resistant *Staphylococcus*

aureus, multiresistant Gram negative organisms, norovirus, respiratory viruses, varicella zoster

virus, and VREfm). However, as not all rooms had ensuite facilities, risk of VREfm transmission

remained. At the time of the study, pathogen surveillance systems in the hospital had not

detected any suspected VREfm outbreak within the study population.

Results of VREfm Screening

In total, 45 rectal swabs from 27 patients were screened for VREfm. Of these, 18 samples from

13 patients were VREfm positive (Table 1). Additionally, three (23.1%) colonised patients

developed VREfm bacteraemia 9, 24, or 46 days after being identified as VREfm carriers. We

applied our sampling strategy to 16 rectal screens generating 224 isolates from 11 patients, and

five blood cultures (five isolates) from two patients yielding a total of 229 isolates. Two rectal

swabs and one blood culture were not available for further study. Most patients were female,

and the median age was 66 years, a range of primary diagnoses were represented in the

patient cohort (Table 1). Most colonised patients had received antibiotics in the preceding six

months, although only 30% had received vancomycin (Table 1).

Simultaneous carriage of multiple VREfm strains

In silico MLST typing using short reads from all 229 isolates showed four sequence types (ST)

from the hospital-associated clade A1 (25) were present in the sample cohort, dominated by

ST80 (n=130) and ST1424 (n=97) (Table 2). ST789 and ST1659 were identified in single

isolates only. Multiple STs were detected in three (27%) samples. Sample VRED06 from patient

P49 carried 10 (71.4%) ST80, three (21.4%) ST1424, and one (7.1%) ST789 isolate; sample

VRED07 from P14 carried 10 (71.4%) ST1424 and four (28.6%) ST80 isolates; sample VRED11

from P50 carried 13 (92.9%) ST1424 and one (7.1%) ST1659 isolate. A further rectal swab

sample from P49 collected two days after VRED06 contained only ST1424, and a blood culture

collected nine days later also contained ST1424. P9 had three rectal swab samples collected

over an 11 day period and had positive blood cultures one month later, all samples contained

ST80 only.

Generation of high quality reference genomes

As 99% of isolates grouped into only two STs we next sought to identify relationships within

these two sequence types. To generate strain-specific reference genomes for further analysis

one ST80 (VRED06-10) isolate and one ST1424 (VRED06-02) isolate were selected for long

read sequencing. Both isolates were from P49 and were from the same swab sample collected

on study day 15. Complete genomes were assembled and polished using the Trycycler pipeline

generating a single circular chromosome and 5-7 plasmids for each isolate (Supplementary

Table 1). BUSCO showed 99.5% complete core genes and indel analysis showed <4% coding

sequences were significantly shorter than the reference match, within the expected range of

truncated genes due to evolutionary processes (26). These results show the assemblies were

complete and contained very few errors.

Genomic population structure of VREfm isolates suggests recent transmission events

The chromosomes of the two strain-specific genome assemblies were used as references for

short read mapping within each sequence type. Within-patient diversity was low when isolates

of the same MLST ST were compared, generally differing by zero SNPs and a maximum

pairwise difference of 4 SNPs (Table 2). Where within-patient isolates were from different STs,

SNP differences were significantly higher as expected (490-4,400 SNPs, Table 2). Similarly,

detection of insertions, deletions, and plasmids were usually shared in isolates from the same

patient. However, the presence of DEL3 (12 bp non-coding deletion) and DEL4 (11 bp deletion

in a solute binding protein) were variable within 24 ST80 isolates from P20 with 0-2

differentiating SNPs (Figure 2). In isolates from P9 p1_VRED06-10 and p3_VRED06-10 were

variably detected despite most genomes having no differentiating SNPs (Figure 2). Where

multiple samples from the same patient were collected over time we found low (0-3 SNPs)

accumulation of SNPs and no pattern in the prevalence of other genomic variants, reflecting the

short study time period.

The ST80 genomes formed a well-structured population with five clear clusters each

separated by >10 SNPs (Figure 2). Within the clusters isolates were closely related, differing by

0-2 SNPs, and were mostly derived from individual patients. However, two clusters included

isolates from two different patients (patients P7 and P33, and P2 and P9), suggesting two

recent transmission events. All the reference plasmids were detected in the P7 and P33 isolates

and there was a difference of two insertions in three isolates. As mentioned above there was

significant variation in detection of p1_VRED06-10 and p3_VRED06-10 plasmids within P9

isolates, although in P2 isolates all plasmids were detected.

Mapping of the ST1424 isolates showed a much more homogeneous population than in

ST80 (Figure 3). Of the 97 ST1424 isolates, 69 had no SNPs and the remaining 28 had 1-2

SNPs differentiating them from the rest of the collection. The SNPs that were detected did not

lead to any clear clustering of isolates, except for the 14 isolates from P6 which all carried a

SNP in a penicillin binding protein which differentiated them from the other ST1424 isolates.

Two of the P6 isolates had further independent SNPs (one each) and another one isolate had

lost p1_VRED06-02. Two isolates from P49 collected on day 17 shared a SNP in a penicillin

binding protein as well as a 13 bp deletion in a non-coding region. The same variants were

detected in a blood culture isolate collected 13 days later. Of note, the specific SNP in these

three P49 isolates was in the same penicillin binding protein gene as the P6 isolates, but a

different region. No insertions were detected in the ST1424 collection, and of the six deletions

found five were only in isolates from P49. Apart from the loss of p6_VRED06-02 mentioned

above, the only other plasmid not detected was p1_VRED06-02 in five isolates from three

patients.

Analysis of multiple VREfm colonies supports transmission resolution

A transmission network was then constructed taking account of the phylogenetic placement of

all 14 colony picks in each sample (Figure 4). The network supports transmission of ST80

between P2 and P9, and between P7 and P33, although P20 appears to be a singleton not

linked to transmission within this patient cohort. Considering patient movements, P9 was

admitted to Ward B prior to the start of the study period and screened positive for VREfm on day

13 of their admission, P2 screened positive on the same day although this was their first day of

admission to Ward B (Figure 1). Both P2 and P9 were admitted through Ward A prior to being

placed on Ward B, although no shared rooms or bed spaces were identified (Supplementary

Figure 1). The directionality or location of this putative transmission event cannot be

ascertained. P7 screened positive on admission to Ward B. P33 was admitted from an external

Health Board to Ward B, screened negative on day 2 of their admission, then screened positive

on day 10 of admission (6 days after P7). No shared rooms or bed spaces were identified for P7

and P33, although given the timings of positive screens it is likely that ST80 VREfm was

transmitted from P7 to P33 on Ward B (Figure 1, Supplementary Figure 1). P20 screened

negative towards the end of a 32 day stay on Ward B, was discharged for 13 days and then

readmitted to Ward B and screened positive on admission, suggesting they may have become

colonised outside of the hospital.

Patients carrying ST1424 all clustered together with P34 having strong links to all other

patients, including likely direct transmission to P6 (Figure 4). P34 was admitted to Ward B from

an external Health Board and screened positive with ST1424 on day 6 of admission, 6 days

later P49 screened positive. P49 was on Ward B two days prior to P34 but screened negative 3

days before P34 was found to be colonised, suggesting P34 was the source of ST1424

transmission to P49. Soon after, P14 was found to be colonised with ST1424 and ST80 on day

2 of admission to Ward B but transmission from P49 is unlikely as ST80 isolates in both patients

were unrelated and P49 had an additional ST789 strain. It is possible that P14 and P49 had

superinfection of ST1424 on top of existing VREfm colonisation. Nine days later, P24 screened

positive with ST1424 on Ward B on their seventh day of admission. P24 shared time on the

ward with all three previously identified carriers, based on genetic similarity of all sequenced

isolates P34 is the most parsimonious source of transmission (Figure 3). P6 and P50 were both

admitted to Ward A on the same day late in the study period, P50 screened positive with

ST1424 and ST1659 on day 2 and P6 screened positive with ST1424 only on day 6. From the

epidemiology it may be assumed that P6 was infected by P50 however, sequencing suggests

the two ST1424 populations may be derived from different hosts, with P6 isolates having all

acquired a single SNP and P50 isolates having multiple different SNPs and all lacking the

p6_VRED06-02 plasmid (Figures 3 and 4). P6 and P50 were the only patients on Ward A to

acquire ST1424, the route of transmission between the two wards is unclear. None of the

patients with ST1424 shared a room or used the same bed space previously used by an

identified ST1424 positive carrier during their stay (Supplementary Figure 1).

Performing the analysis again with three, five, or ten genomes per screening sample did

not change the transmission inference for ST80 isolates (although higher confidence was

achieved with five or more genomes), but there was significant variability in the ST1424 cluster

due to low diversity in the genomes (Supplementary Figure 2). Within ST1424 it was only

possible to reliably link all patients and give high confidence that P34 was the main driver in the

cluster with 14 isolates.

Plasmids were mostly ST-specific

Focusing on the plasmids identified in the reference isolates, VRED06-02 (ST1424) contained

seven plasmids, and VRED06-10 (ST80) contained five plasmids. Plasmids in the two isolates

were not particularly similar, suggesting there was limited sharing of plasmids between the two

isolates within P49 at the time of sampling (Supplementary Table 2).

We then sought to identify carriage of similar plasmids in the entire isolate collection by

mapping the short reads to each assembled plasmid (Supplementary Table 3). This showed

that for the most part plasmids were ST-specific as there were few examples of ST1424 isolates

carrying plasmids from the ST80 reference, and *vice versa*. However, all ST80 isolates from P7

and P33 carried p7_VRED06-02 from ST1424, and almost all isolates appeared to carry

p4_VRED06-10. p4_VRED06-02 and p4_VRED06-10 had the closest pairwise identity

(Supplementary Table 2), with mash distance of 0.05 and average nucleotide identity of 89%

over 4.3 kb. As p4_VRED06-10 is slightly smaller, we believe the hits against the ST1424

isolates here are due to cross-mapping of reads from the related p4_VRED06-02. P7_VRED06-

02 carriage in P7 and P33 does not look like a false positive as it is unrelated to others in the

collection (Supplementary Table 2), but no close links to any ST1424 positive patients were

identified for P7 and P33 (Figure 4), so the source of this plasmid is unclear. We also found the

single ST1659 isolate from P50 had an identical plasmid profile to 12 ST1424 isolates in the

same sample, and the single ST789 isolate from P49 had the same plasmid profile as 10 ST80

isolates in the same patient sample.

AMR gene load differs between closely related isolates

We next sought to determine the variability of AMR genes within the collection (Figure 5). In

total 13 AMR genes were detected with three (23.1%) present in all isolates, five (38.5%) genes

(*ant(9)-Ia*, *dfrG*, *erm(A)*, and *tet(M)*) only in ST1424 isolates and two (15.4%) genes (*ant(6)-Ia*

and *tet(S)*) found only in ST80 isolates. Tetracycline resistance gene *tet(M)* was found in 62.2%

of ST1424 and ST1659 genomes and the aminoglycoside resistance gene *aac(6')-aph(2'')* was

found in 69.9% of all genomes (Table 3 and Figure 5).

tet(M) was identified on the chromosome of VRED06-02, as part of Tn*6944* first

identified in *C. difficile* (Supplementary Figure 3A). Excision of Tn*6944* is likely responsible for

variable presence of *tet(M).*

aac(6')-aph(2'') was present on p1_VRED06-02 (ST80) and p1_VRED06-10 (ST1424).

In p1_VRED06-02, two copies of *aac(6')-aph(2'')* were surrounded by insertion sequences

IS*256*, IS*1216*, and IS*3,* potentially providing multiple mechanisms of excision. *aac(6')-aph(2'')*

was not detected in any ST80 isolates that were p1_VRED06-02 negative, although only 60.2%

(n=65) of isolates that carried this plasmid also carried *aac(6')-aph(2''),* highlighting that

although the cassette was linked to p1_VRED06-02 it may have been excised in some cases. In

ST1424 p1_VRED06-10, *aac(6')-aph(2'')* was surrounded by two copies of IS*256* and carried

genes including *erm(B)* with similarity to Tn*6218* first identified in *C. difficile*, although the

transposition machinery was missing (Supplementary Figure 3B) (27). In ST1424 *aac(6')-*

aph(2'') was detected in 97.8% (n=90) isolates with p1_VRED06-10 but was also found in four

isolates that lacked this plasmid (Table 3 and Figure 5). Short read assemblies were too

fragmented to fully resolve the location of the gene in these four cases, but three of the

assemblies did show *aac(6')-aph(2'')* in association with an IS*3* gene suggesting it had

mobilised to another genetic element within the cell.

The tetracycline resistance gene *tet(L)* was identified in a single ST1659 isolate, the

gene was co-located with *tet(M)* on a 30 kb contig that was similar to Tn*6248* from *E. faecium*

over ~19 kb (Supplementary Figure 3C).

DISCUSSION

By taking account of within-patient diversity in VREfm carriage populations we identified

unknown links between patients that could supplement efforts to control transmission within

hospitals. We also show that diversity exists not just at the level of SNPs – AMR gene

presence/absence, indels, and plasmid presence all vary within and between patients. The

relative importance of each of these layers of diversity for understanding bacterial transmission

and evolution are key for future WGS based analyses.

Identified transmission clusters

We identified an ST1424 transmission cluster involving six patients and two ST80

clusters involving two patients (Figure 4). The ST80 population appeared relatively stable

otherwise, with three clusters of isolates belonging to individual patients. However, in P14 and

P49 where ST1424 and ST80 isolates were both present in carriage samples we did not detect

transmission of ST80 suggesting these individuals were infected by an ST1424 on top of

existing VREfm carriage, or a wide transmission bottleneck and acquisition of both lineages at

the same time from an undetermined source.

Power calculation determined 14 colonies to be the minimum needed to sequence per

sample to ensure reliable detection of a variant making up 20% of the within-patient population.

This successfully identified minor population variants in 27% of patients. We also performed

transmission inference with three, five, and ten isolates per rectal sample and found that the

strength and accuracy of transmission inference increased as the number of isolates per patient

increased (Figure 4 and Supplementary Figure 2). Sequencing more than 14 colonies would

further improve the detection of minor variants but would also increase the costs of sequencing

and turnaround time. Our findings show that sequencing single colonies without considering

within patient diversity in suspected VREfm outbreaks will miss some putative transmission

events, but the implementation of sequencing multiple colonies into routine use will require

careful thought and validation as there was low within-patient diversity in most cases in our

collection. Alternatively, strain-resolved metagenomics directly on clinical samples or

sequencing sweeps of selective culture growth may be more feasible in future (28–30). Further

work is required to determine the optimum sampling strategy to support infection prevention and

control investigations in healthcare settings.

We identified three (27%) patients that carried two or three different strains at the same

time (Table 2). This in line with recent studies that identified up to half of patients carry 2-4

different *E. faecium* strains and within-patient diversity varies over time, with identical AMR

elements passing between unrelated strains within patients (20,24,31,32). These findings

highlight the challenges of tracking and controlling highly variable *E. faecium* populations within

healthcare settings, particularly when relying on single colony picks and only short read

sequencing which cannot fully resolve most plasmids.

We found very little SNP-based diversification over time in our study, with ST1424

isolates often being identical to isolates collected weeks earlier, although we did identify a

defining SNP in the P6 isolates collected late in the study (Figure 3). Estimates of diversification

rates in *E. faecium* from national single colony sampling suggest 7 mutations per year (33),

although other studies of longitudinal within-patient diversification have estimated higher rates of

12.6 – 128 mutations per year (20,22,23). The low SNP diversity identified in our one-month

collection of carriage isolates is in keeping with these mutation rates, although it is perhaps

unexpected that in the four P9 bloodstream isolates only one SNP was detected in one isolate

compared to rectal samples collected 35-37 days previously (Figure 2). The low SNP level

diversity leads to difficulty in reliably inferring specific transmission events within ST1424, as

multiple potential transmission events are plausible, as reflected in the transmission network

(Figure 4).

Variability in AMR and Mobile Elements

We identified some variability of AMR gene carriage within patients, probably related to

loss of mobile elements (Table 3 and Figure 5). However, the impact on phenotype is unclear –

all isolates carried *aac(6')-Ii* and *aph(3')-III* which together confer high level resistance to the

clinically relevant aminoglycosides amikacin and gentamicin, so the loss of *aac(6')-aph(2'')* may

be more efficient for the cell without an overt phenotypic change in minimum inhibitory

concentration. *tet(M)* was present in 62% of ST1424 genomes but no other tetracycline

resistance genes were found in these isolates, so this variability could have impacts on clinical

reporting depending on which colony is selected for antibiotic susceptibility testing. However,

tetracyclines are not generally used for direct treatment of enterococcal human infections so the

clinical impact of this variability will be limited. Similar variable presence of the vancomycin

resistance element within patients has been described elsewhere and could lead to inadvertent

use of vancomycin even when the patient harbours a resistant population (20,21,34,35).

We identified a linear plasmid (p2_VRED06-10) carrying *vanA* in our ST80 reference

genome. Boumasmoud *et al* (36) recently described the linear plasmid pELF_USZ in VREfm

from Switzerland that carried an operon conferring the ability to utilise the human gut mucin N-

acetyl-galactosamine; however, p2_VRED06-02 did not carry this operon. The advent of long

read sequencing has allowed the increasing identification of linear plasmids, and their impact on

niche adaptation remains to be fully elucidated (36–40).

We recognise some limitations. Around 60% of *E. faecium* carriers in hospitals can be

linked to nosocomial transmission either from other patients or reservoirs in the hospital

environment (31,41–44). Our study did not include environmental samples, although patients

were mostly located in individual rooms. Bathroom facilities were shared posing a significant

environmental reservoir for VREfm. Also, we relied on direct plating to solid VREfm screening

agar for inclusion in our study. Previous studies have shown a sensitivity of 58-96% for this

approach, rising to 97-100% with a pre-enrichment step (45–47). In our study, P49 carried

ST1424, ST80, and ST789 on their first positive screen having been negative for VREfm 11

days previously, suggesting either infection with a mixed population from another host not

detected by our sampling strategy or an initial false negative VREfm screen. Our focus on

VREfm is another potential limitation as vancomycin sensitive *E. faecium* may contribute to

transmission clusters causing significant disease and could gain/lose the resistance mechanism

during transmission as described by Raven *et al* (33) – although isolates in the identified

clusters were collected over years rather than weeks in our study. Despite these limitations, we

believe our study are applicable to current practice as surveillance systems are mainly focussed

on significant antimicrobial resistance phenotypes such as vancomycin resistance. Routine,

prospective, genomic surveillance over longer periods than our study may be more suited to a

resistance agnostic approach to understanding nosocomial spread of pathogenic bacteria (31).

Our findings suggest that sequence-based surveillance of VREfm screening samples

would be useful in identifying outbreaks proactively. A proactive approach would avoid large

outbreaks of infection, reduce costs of ward closure and the clinical impact of invasive disease

(48–51). In our setting an outbreak of VREfm was suspected 3 weeks after the study collection

period when P9 and P49 developed bloodstream infection concurrently but this was many

weeks after VREfm transmission had likely occurred (Figure 1 and Figure 4). Due to the

retrospective nature of our study, we were not able to use the findings from sequencing to

directly influence patient care.

CONCLUSION

We have shown that sequencing 14 VREfm carriage isolates per patient improved resolution of

possible transmission pathways. This has implications for outbreak investigations which may

miss possible transmission events if only single colonies are investigated. We also show the

utility of long read sequencing to supplement routine short read sequencing to generate high-

quality, closed reference genomes and allow identification of non-SNP variation such as indels,

AMR genes, and plasmid loss/gain events which can be used for fine-level discrimination within

suspected bacterial outbreaks.

MATERIAL AND METHODS

Bacterial Isolates

Screening for VREfm intestinal carriage was performed by taking rectal swabs as part of

admission sampling pre-chemotherapy/transplant, and on all inpatients on the haematology unit

developing febrile neutropenia (defined as neutrophils $<0.9x10^9$/l or $<1.0x10^9$/l and falling after

chemotherapy, plus body temperature ≥38°C). Swabs were plated to CHROMID® VRE agar

(bioMérieux, Marcy-l'Étoile, France) and incubated at 37°C in air. Plates were examined for

growth at 24 and 48 hours. Growth of purple colonies were presumed VREfm and a single

colony was subcultured to Columbia blood agar plates (Oxoid, Basingstoke, UK) with a 5 μg

vancomycin disc. Species identification was confirmed by MALDI-TOF on a Microflex instrument

(Bruker, Billerica, USA), and the first positive isolate per patient had antimicrobial susceptibility

determined on the VITEK2 system AST-P607 card (bioMérieux). Once confirmed as VREfm, all

purple colonies were removed from the initial screening plate within 24 hours and stored at -

80°C in a Microbank cryovial (Pro-Lab Diagnostics, Birkenhead, UK). Any VREfm isolated from

clinical samples (blood, wounds, or urine samples) within 60 days of the patient being identified

as a VREfm carrier were also stored. Electronic records were reviewed for demographic and

inpatient stay metadata. Patient movements were visualised with HAIviz v0.3

(https://haiviz.beatsonlab.com/). This work used excess diagnostic material and was approved

by the NHS Scotland BioRepository Network (Ref TR000126) and University of St Andrews

Research Ethics Committee (Ref MD12651).

DNA Extraction

Two cryobank beads were used to inoculate a CHROMID® VRE agar plate and incubated for

20-24 hours at 37°C in air. Fourteen purple colonies were selected at random, each inoculated

into 5 ml of brain heart infusion broth (Oxoid) and incubated at 37°C for 20-24 hours. Bacterial

cells were pelleted by centrifugation (3000 g, 10 min), resuspended in 400 μl Buffer P1 (Qiagen,

Hilden, Germany), and 200 μl used for DNA extraction.

Cells were lysed with 20 μl lysozyme (100 mg/ml) (Sigma-Aldrich, Dorset, England) at

37°C for 60 min, followed by 30 μl Proteinase K (Qiagen) at 56°C for 60 min, and RNA was

digested with 4 μl RNase A (Qiagen) at 37°C for 45 min. DNA was extracted from lysates on the

QiaSymphony instrument using the DNA Mini kit (Qiagen) and protocol

Tissue_HC_200_V7_DSP. DNA concentration was determined from 2 μl extract with the Qubit

BR Kit (ThermoFisher Scientific, Basingstoke, UK) on a Qubit 3.0 fluorometer, extract purity was

assessed with a Nanodrop 1000 (ThermoFisher Scientific).

Isolates were processed in batches of 24, with every 8th position being 5 ml of

uninoculated BHI as a negative control to identify possible carry-over contamination. Negative

controls were processed as above and assessed for purity using the Qubit HS Kit

(ThermoFisher Scientific) in triplicate. Negative controls were accepted if DNA concentration

was <0.5 ng/μl in all replicates.

Genome Sequencing

Short read libraries were prepared using the Nextera XT kit (Illumina, San Diego, USA) and

sequenced with a MiSeq instrument (Illumina) using 300 bp paired-end reads on a 600-cycle v3

reagent kit.

Extracts from two isolates representative of the main clades identified in the collection

were selected for long read sequencing. Long read libraries were generated with the LSK109

Ligation Sequencing Kit (Oxford Nanopore Technologies, Oxford, UK) and sequenced for 8h

using an R9.4 flow cell on a GridION sequencer (Oxford Nanopore Technologies). High

accuracy real time basecalling was performed in MinKNOW v19.12.6 (Oxford Nanopore

Technologies).

Sequence data from this study has been deposited in the NCBI under BioProject

accession number PRJNA877253 (https://www.ncbi.nlm.nih.gov/bioproject/PRJNA877253).

Sequence Assembly and Mapping

Long reads were filtered to remove <1000 bp fragments using Nanofilt v2.7.1 (52), then trimmed

with Porechop v0.3.2 (https://github.com/rrwick/Porechop) to remove adapters and split chimeric

reads. Genome assemblies were generated with Trycycler v0.3.3 (53). Trycycler makes multiple

long read assemblies from read subsets and produces a consensus long read assembly which

is then polished with long and short reads. Four assemblies were generated using Flye v2.8.1,

Redbean v2.5, Raven v1.1.10, and Miniasm v0.1.3 (54–57), giving 12 assemblies in total. The

final consensus assembly was polished with Medaka v0.11.5

(https://github.com/nanoporetech/medaka) and Pilon v1.23 (58), the latter for 2-3 cycles until no

further changes were made. Assembly quality was assessed with assembly-stats v1.0.1

(https://github.com/sanger-pathogens/assembly-stats), Ideel (https://github.com/phiweger/ideel)

and Busco v4.1.4 (59).

Hybrid assemblies were annotated with Prokka v1.14.6 (60). Abricate v1.0.1

(https://github.com/tseemann/abricate) was used to identify matches to the ResFinder,

VirulenceFinder, and PlasmidFinder databases in the assembled contigs (61–64). Putative

prophages were identified with PHASTER (65), and recombination blocks were identified with

Gubbins v2.4.1 (66).

Short reads were quality trimmed with Trimmomatic v0.32 (67) and settings

MAXINFO:200:0.4. MLSTs were determined from the short reads using SRST2 v0.2.0 (68) and

the *E. faecium* pubMLST database (69). For mapping to reference genomes a core alignment

was generated by mapping short reads with Snippy v4.6.0 (https://github.com/tseemann/snippy)

and masking all putative transposases, complete prophage regions, and recombination blocks.

For mapping to reference genomes, a core alignment was generated by mapping short reads

with Snippy v4.6.0 (https://github.com/tseemann/snippy) and masking all putative transposases,

complete prophage regions, and recombination blocks. Non-ACGT bases were converted to N

with snippy-clean and then the variant sites were retained with snp-sites v2.5.1 (70). Maximum-

likelihood phylogenies were constructed with IQTree v2.0.3 from the core SNP alignment with

automatic model selection and 1000 ultrafast bootstraps (71–73). Phylogenies were visualised

with iTOL (74). Short read assemblies were generated with Unicycler v0.4.8 (75) and searched

for antimicrobial resistance genes using Abricate and the ResFinder database.

Transmission Network Inference

Short reads were mapped to the VRED06-10 ST80 reference chromosome with Snippy, the V24

E. faecium ST80 genome (Accession CP036151) was included as an outgroup. A core

alignment was generated as above then a posterior set of phylogenies were generated with

MrBayes v3.2.7 (76). Two MCMC runs consisting of four coupled chains were run for 5,000,000

generations and sampled every 5000 generations. At the completion of the run the standard

deviation of split frequencies was 0.013, the log likelihood was stable, and the effective sample

size of the prior, likelihood, and all numerical parameters was >800. A random sample of 100

trees from the MrBayes posterior set were used as input for Phyloscanner v1.6.6 (77).

Parsimony reconstruction was performed in Phyloscanner using the Sankoff algorithm and *k*

parameter of 281494.5, equivalent to a within patient diversity threshold of 10 SNPs. The host

relationship summary was then used to construct a transmission network in Cytoscape v3.9.0

(78), only edges with complex or transmission state and >0.5 probability were visualised.

Plasmid Detection

As described by Pinholt *et al* (37), to detect plasmids in the entire collection, short reads were

mapped to plasmids from the two complete assemblies using Snippy. Plasmids were

considered present if ≥85% bases were called with <20 SNPs/1000 bp.

Statistical Analysis

To determine the optimal number of colonies to analyse for within-sample diversity a power

calculation was performed as described by Huebner er al (79):

$$q \wedge n = (1 - P)$$

Where q = 1 – concentration of organisms, $\wedge$ = exponentiation operator, n = number of colonies

sequenced, and P = probability of finding one or more variants.

Population variants were considered distinct if they differed by >10 chromosomal SNPs.

Moradigaravand *et al* (20) have shown within-patient populations of VREfm can harbour

minority variants at 20-50% of the total population based on sequencing ~5 colonies. To detect

a variant at 20% of the population with 95% confidence would require 14 colonies per sample so

this was selected for analysis of faecal population diversity in this study. However, more in

depth sequencing of blood culture isolates showed much lower diversity – no minor population

variants from ~10 colonies (20) – therefore single colonies from blood culture samples were

sequenced in this study to identify the sequence type causing invasive disease.

Presence/absence matrices of AMR genes were generated in R v4.0.5 using ggplot2

and patchwork packages (80–82).

ACKNOWLEDGEMENTS

This work was supported by the Chief Scientist Office (Scotland) through the Scottish

Healthcare Associated Infection Prevention Institute (Reference SIRN/10). The authors

acknowledge the Research/Scientific Computing teams at The James Hutton Institute and NIAB

for providing computational resources and technical support for the "UK's Crop Diversity

Bioinformatics HPC" (BBSRC grant BB/S019669/1), use of which has contributed to the results

reported within this paper. Bioinformatics and Computational Biology analyses were further

supported by the University of St Andrews Bioinformatics Unit which is funded by a Wellcome

Trust ISSF award [grant 105621/Z/14/Z].

AUTHOR CONTRIBUTIONS

487   M.P.M., S.H.G., K.E.T., and M.T.G.H. conceived the project. S.H.G., K.E.T., and M.T.G.H.

488   supervised the project. M.P.M. and K.A.P. performed genome sequencing. M.P.M. performed

489   data analysis. M.P.M. and M.T.G.H. wrote the manuscript. M.T.G.H., S.H.G., T.J.E., and A.L.

490   secured funding for the project. All authors reviewed and approved the manuscript.

COMPETING INTERESTS

494   The authors declare no competing interests

ETHICS DECLARATIONS

Access to isolates and clinical data was approved by the NHS Scotland Biorepository Network

(Ref TR000126) and University of St Andrews Research Ethics Committee (Ref MD12651).

REFERENCES

1. Arias CA, Murray BE. The rise of the Enterococcus: beyond vancomycin resistance. Nat Rev Microbiol. 2012;10:266–78.

2. WHO. WHO publishes list of bacteria for which new antibiotics are urgently needed [Internet]. 2017 [cited 2022 Apr 26]. Available from: https://www.who.int/news/item/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed

3. CDC. Antibiotic Resistance Threats in the United States, 2019. Atlanta, GA: U.S. Department of Health and Human Services, CDC; 2019.

4. Ong DSY, Bonten MJM, Safdari K, Spitoni C, Frencken JF, Witteveen E, et al. Epidemiology, management, and risk-adjusted mortality of ICU-acquired enterococcal bacteremia. Clin Infect Dis. 2015;61(9):1413–20.

5. Billington EO, Phang SH, Gregson DB, Pitout JDD, Ross T, Church DL, et al. Incidence, Risk Factors, and Outcomes for Enterococcus spp . Blood Stream Infections: A Population-Based Study. Int J Infect Dis. 2014;26:76–82.

6. Dik JWH, Dinkelacker AG, Vemer P, Lo-Ten-Foe JR, Lokate M, Sinha B, et al. Cost-analysis of seven nosocomial outbreaks in an academic hospital. PLoS ONE. 2016;11(2):1–7.

7. Lloyd-Smith P, Younger J, Lloyd-Smith E, Green H, Leung V, Romney MG. Economic analysis of vancomycin-resistant enterococci at a Canadian hospital: Assessing attributable cost and length of stay. J Hosp Infect. 2013;85(1):54–9.

8. ARHAI Scotland. Scottish One Health Antimicrobial Use and Antimicrobial Resistance in 2020. ARHAI Scotland; 2021.

9. Zhou X, Willems RJL, Friedrich AW, Rossen JWA, Bathoorn E. Enterococcus faecium: from microbiological insights to practical recommendations for infection control and diagnostics. Antimicrob Resist Infect Control. 2020 Aug 10;9(1):130.

10. Quainoo S, Coolen JPM, van Hijum SAFT, Huynen MA, Melchers WJG, van Schaik W, et
al. Whole-Genome Sequencing of Bacterial Pathogens: the Future of Nosocomial Outbreak
Analysis. Clin Microbiol Rev. 2017 Oct 30;30(4):1015–63.

11. Pinholt M, Larner-Svensson H, Littauer P, Moser CE, Pedersen M, Lemming LE, et al.
Multiple hospital outbreaks of vanA Enterococcus faecium in Denmark, 2012-13,
investigated by WGS, MLST and PFGE. J Antimicrob Chemother. 2015;70:1–9.

12. Croucher NJ, Didelot X. The application of genomics to tracing bacterial pathogen
transmission. Curr Opin Microbiol. 2015 Feb 1;23:62–7.

13. Bryant JM, Grogono DM, Greaves D, Foweraker J, Roddick I, Inns T, et al. Whole-genome
sequencing to identify transmission of Mycobacterium abscessus between patients with
cystic fibrosis: a retrospective cohort study. The Lancet. 2013;381(9877):1551–60.

14. Worby CJ, Lipsitch M, Hanage WP. Within-Host Bacterial Diversity Hinders Accurate
Reconstruction of Transmission Networks from Genomic Distance Data. PLoS Comput Biol.
2014;10(3):e1003549.

15. Snitkin ES, Zelazny AM, Thomas PJ, Stock F, NISC COMPARATIVE SEQUENCING
PROGRAM, Henderson DK, et al. Tracking a Hospital Outbreak of Carbapenem-Resistant
Klebsiella pneumoniae with Whole-Genome Sequencing. Sci Transl Med.
2012;4(148):148ra116.

16. Hall MD, Holden MT, Srisomang P, Mahavanakul W, Wuthiekanun V, Limmathurotsakul D,
et al. Improved characterisation of MRSA transmission using within-host bacterial sequence
diversity. eLife. 2019;8:e46402.

17. Harris SR, Cartwright EJ, Török ME, Holden MT, Brown NM, Ogilvy-Stuart AL, et al. Whole-
genome sequencing for analysis of an outbreak of meticillin-resistant Staphylococcus
aureus: a descriptive study. Lancet Infect Dis. 2013;13(2):130–6.

18. Okoro CK, Kingsley RA, Quail MA, Kankwatira AM, Feasey NA, Parkhill J, et al. High-
Resolution Single Nucleotide Polymorphism Analysis Distinguishes Recrudescence and
Reinfection in Recurrent Invasive Nontyphoidal Salmonella Typhimurium Disease. Clin
Infect Dis. 2012;54(7):955–63.

19. Paterson GK, Harrison EM, Murray GGR, Welch JJ, Warland JH, Holden MTG, et al.
Capturing the cloud of diversity reveals complexity and heterogeneity of MRSA carriage,
infection and transmission. Nat Commun. 2015;6(6560).

20. Moradigaravand D, Gouliouris T, Blane B, Naydenova P, Ludden C, Crawley C, et al.
Within-host evolution of Enterococcus faecium during longitudinal carriage and transition to
bloodstream infection in immunocompromised patients. Genome Med. 2017;9(1):119.

21. Raven KE, Gouliouris T, Parkhill J, Peacock SJ. Genome-Based Analysis of Enterococcus
faecium Bacteremia Associated with Recurrent and Mixed-Strain Infection. Carroll KC,
editor. J Clin Microbiol. 2018;56(3):e01520-17.

22. Dubin KA, Mathur D, McKenney PT, Taylor BP, Littmann ER, Peled JU, et al. Diversification and evolution of vancomycin-resistant Enterococcus faecium during intestinal domination. Infect Immun. 2019;87:e00102-19.

23. Bayjanov JR, Baan J, Rogers MRC, Troelstra A, Willems RJL, van Schaik W. Enterococcus faecium genome dynamics during long-term asymptomatic patient gut colonization. Microb Genomics. 2019;5.

24. Both A, Kruse F, Mirwald N, Franke G, Christner M, Huang J, et al. Population dynamics in colonizing vancomycin-resistant E. faecium isolated from immunosuppressed patients. J Glob Antimicrob Resist. 2022;28:267–73.

25. Lebreton F, Schaik W van, McGuire AM, Godfrey P, Griggs A, Mazumdar V, et al. Emergence of Epidemic Multidrug-Resistant Enterococcus faecium from Animal and Commensal Strains. mBio. 2013;4(4):e00534-13.

26. Goodhead I, Darby AC. Taking the pseudo out of pseudogenes. Curr Opin Microbiol. 2015;23:102–9.

27. Dingle KE, Elliott B, Robinson E, Griffiths D, Eyre DW, Stoesser N, et al. Evolutionary History of the Clostridium difficile Pathogenicity Locus. Genome Biol Evol. 2014;6(1):36–52.

28. Mäklin T, Kallonen T, David S, Boinett CJ, Pascoe B, Méric G, et al. High-resolution sweep metagenomics using fast probabilistic inference. Vol. 5, Wellcome Open Research. 2021.

29. Anyansi C, Straub TJ, Manson AL, Earl AM, Abeel T. Computational Methods for Strain-Level Microbial Detection in Colony and Metagenome Sequencing Data. Front Microbiol. 2020;11.

30. Mu A, Kwong JC, Isles NS, Silva AG da, Schultz MB, Ballard SA, et al. Reconstruction of the Genomes of Drug-Resistant Pathogens for Outbreak Investigation through Metagenomic Sequencing. mSphere. 2019 Feb 27;4(1):e00529-18.

31. Gouliouris T, Coll F, Ludden C, Blane B, Raven KE, Naydenova P, et al. Quantifying acquisition and transmission of Enterococcus faecium using genomic surveillance. Nat Microbiol. 2021 Jan;6(1):103–11.

32. Brodrick HJ, Raven KE, Harrison EM, Blane B, Reuter S, Török ME, et al. Whole-genome sequencing reveals transmission of vancomycin-resistant Enterococcus faecium in a healthcare network. Genome Med. 2016;8(1):4.

33. Raven KE, Gouliouris T, Brodrick H, Coll F, Brown NM, Reynolds R, et al. Complex Routes of Nosocomial Vancomycin-Resistant Enterococcus faecium Transmission Revealed by Genome Sequencing. Clin Infect Dis. 2017;64(7):886–93.

34. Xanthopoulou K, Wille J, Zweigner J, Lucaßen K, Wille T, Seifert H, et al. Characterization of a vancomycin-resistant Enterococcus faecium isolate and a vancomycin-susceptible E. faecium isolate from the same blood culture. J Antimicrob Chemother. 2020;76(4):883–6.

35. Cárdenas AM, Andreacchio KA, Edelstein PH. Prevalence and detection of mixed-
population enterococcal bacteremia. J Clin Microbiol. 2014;52(7):2604–8.

36. Boumasmoud M, Dengler Haunreiter V, Schweizer TA, Meyer L, Chakrakodi B, Schreiber
PW, et al. Genomic Surveillance of Vancomycin-Resistant Enterococcus faecium Reveals
Spread of a Linear Plasmid Conferring a Nutrient Utilization Advantage. mBio.
2022;13(2):e03771-21.

37. Pinholt M, Bayliss SC, Gumpert H, Worning P, Jensen VVS, Pedersen M, et al. WGS of
1058 Enterococcus faecium from Copenhagen, Denmark, reveals rapid clonal expansion of
vancomycin-resistant clone ST80 combined with widespread dissemination of a vanA-
containing plasmid and acquisition of a heterogeneous accessory genome. J Antimicrob
Chemother. 2019;74(7):1776–85.

38. Hashimoto Y, Taniguchi M, Uesaka K, Nomura T, Hirakawa H, Tanimoto K, et al. Novel
Multidrug-Resistant Enterococcal Mobile Linear Plasmid pELF1 Encoding vanA and vanM
Gene Clusters From a Japanese Vancomycin-Resistant Enterococci Isolate. Front
Microbiol. 2019;10.

39. Hashimoto Y, Kita I, Suzuki M, Hirakawa H, Ohtaki H, Tomita H. First Report of the Local
Spread of Vancomycin-Resistant Enterococci Ascribed to the Interspecies Transmission of
a vanA Gene Cluster-Carrying Linear Plasmid. mSphere. 2020;5(2):e00102-20.

40. Fujiya Y, Harada T, Sugawara Y, Akeda Y, Yasuda M, Masumi A, et al. Transmission
dynamics of a linear vanA-plasmid during a nosocomial multiclonal outbreak of vancomycin-
resistant enterococci in a non-endemic area, Japan. Sci Rep. 2021;11(1):14780.

41. Lee AS, White E, Monahan LG, Jensen SO, Chan R, van Hal SJ. Defining the Role of the
Environment in the Emergence and Persistence of vanA Vancomycin-Resistant
Enterococcus (VRE) in an Intensive Care Unit: A Molecular Epidemiological Study. Infect
Control Hosp Epidemiol. 2018;1–8.

42. Ford CD, Lopansri BK, Gazdik MA, Webb B, Snow GL, Hoda D, et al. Room contamination,
patient colonization pressure, and the risk of vancomycin-resistant Enterococcus
colonization on a unit dedicated to the treatment of hematologic malignancies and
hematopoietic stem cell transplantation. Am J Infect Control. 2016;44(10):1110–5.

43. McDermott H, Skally M, O'Rourke J, Humphreys H, Fitzgerald-Hughes D. Near-patient
environmental contamination of an intensive care unit with Vancomycin-resistant
Enterococci (VRE) and Extended-Spectrum Beta-Lactamase–Producing
Enterobacteriaceae (ESBL-E) before and after the introduction of chlorhexidine bathing for
patients. Infect Control Hosp Epidemiol. 2018;1–2.

44. Bonten MJM, Hayden MK, Nathan C, Van Voorhis J, Matushek M, Slaughter S, et al.
Epidemiology of colonisation of patients and environment with vancomycin-resistant
enterococci. Lancet. 1996;348(9042):1615–9.

45. Gouliouris T, Blane B, Brodrick HJ, Raven KE, Ambridge KE, Kidney AD, et al. Comparison
of two chromogenic media for the detection of vancomycin-resistant enterococcal carriage
by nursing home residents. Diagn Microbiol Infect Dis. 2016;85(4):409–12.

46. D'Agata EMC, Gautam S, Green WK, Tang YW. High rate of false-negative results of the
rectal swab culture method in detection of gastrointestinal colonization with vancomycin-
resistant enterococci. Clin Infect Dis. 2002;34(2):167–72.

47. Linfield RY, Campeau S, Injean P, Gregson A, Kaldas F, Rubin Z, et al. Practical methods
for effective vancomycin-resistant enterococci (VRE) surveillance: experience in a liver
transplant surgical intensive care unit. Infect Control Hosp Epidemiol. 2018;39(10):1178–82.

48. Gordon LG, Elliott TM, Forde B, Mitchell B, Russo PL, Paterson DL, et al. Budget impact
analysis of routinely using whole-genomic sequencing of six multidrug-resistant bacterial
pathogens in Queensland, Australia. BMJ Open. 2021;11(2):e041968.

49. Torok E, Brodrick H, Khokhar F, Blane B, Polgarova P, Brown J, et al. Prospective
Surveillance and Rapid Whole-Genome Sequencing Detects Two Unsuspected Outbreaks
of Carbapenemase-Producing Klebsiella pneumoniae in a UK Teaching Hospital. Open
Forum Infect Dis. 2017;4(Suppl 1):S43–4.

50. Sherry NL, Gorrie CL, Kwong JC, Higgs C, Stuart RL, Marshall C, et al. Multi-site
implementation of whole genome sequencing for hospital infection control: A prospective
genomic epidemiological analysis. Lancet Reg Health - West Pac. 2022;23:100446.

51. Forde BM, Bergh H, Cuddihy T, Hajkowicz K, Hurst T, Playford EG, et al. Clinical
implementation of routine whole-genome sequencing for hospital infection control of multi-
drug resistant pathogens [Internet]. medRxiv; 2022 [cited 2022 Aug 23]. p.
2022.05.02.22273921. Available from:
https://www.medrxiv.org/content/10.1101/2022.05.02.22273921v1

52. De Coster W, D'Hert S, Schultz DT, Cruts M, Van Broeckhoven C. NanoPack: visualizing
and processing long-read sequencing data. Bioinformatics. 2018;34(15):2666–9.

53. Wick RR, Judd LM, Cerdeira LT, Hawkey J, Méric G, Vezina B, et al. Trycycler: consensus
long-read assemblies for bacterial genomes. Genome Biol. 2021;22(1):266.

54. Kolmogorov M, Yuan J, Lin Y, Pevzner PA. Assembly of long, error-prone reads using
repeat graphs. Nat Biotechnol. 2019;37(5):540–6.

55. Ruan J, Li H. Fast and accurate long-read assembly with wtdbg2. Nat Methods.
2020;17(2):155–8.

56. Vaser R, Šikić M. Time- and memory-efficient genome assembly with Raven. Nat Comput
Sci. 2021;1(5):332–6.

57. Li H. Minimap and miniasm: fast mapping and de novo assembly for noisy long sequences.
Bioinformatics. 2016;32(14):2103–10.

58. Bruce J Walker, Thomas Abeel, Terrance Shea, Margaret Priest, Amr Abouelliel, Sharadha
Sakthikumar, et al. Pilon: An Integrated Tool for Comprehensive Microbial Variant Detection
and Genome Assembly Improvement | PLOS ONE. PLOS ONE. 2014;9(11):e112963.

59. Simão FA, Waterhouse RM, Ioannidis P, Kriventseva EV, Zdobnov EM. BUSCO: assessing
genome assembly and annotation completeness with single-copy orthologs. Bioinformatics.
2015 Oct 1;31(19):3210–2.

60. Seemann T. Prokka: Rapid prokaryotic genome annotation. Bioinformatics.
2014;30(14):2068–9.

61. Bortolaia V, Kaas Rs, Ruppe E, Roberts Mc, Schwarz S, Cattoir V, et al. ResFinder 4.0 for
predictions of phenotypes from genotypes. J Antimicrob Chemother. 2020;75(12).

62. Zankari E, Allesøe R, Joensen KG, Cavaco LM, Lund O, Aarestrup FM. PointFinder: a novel
web tool for WGS-based detection of antimicrobial resistance associated with chromosomal
point mutations in bacterial pathogens. J Antimicrob Chemother. 2017;72(10):2764–8.

63. Joensen Kg, Scheutz F, Lund O, Hasman H, Kaas Rs, Nielsen Em, et al. Real-time whole-
genome sequencing for routine typing, surveillance, and outbreak detection of verotoxigenic
Escherichia coli. J Clin Microbiol. 2014;52(5).

64. Carattoli A, Zankari E, Garciá-Fernández A, Larsen MV, Lund O, Villa L, et al. In Silico
detection and typing of plasmids using plasmidfinder and plasmid multilocus sequence
typing. Antimicrob Agents Chemother. 2014;58(7):3895–903.

65. Arndt D, Grant JR, Marcu A, Sajed T, Pon A, Liang Y, et al. PHASTER: a better, faster
version of the PHAST phage search tool. Nucleic Acids Res. 2016;1–6.

66. Croucher NJ, Page AJ, Connor TR, Delaney AJ, Keane JA, Bentley SD, et al. Rapid
phylogenetic analysis of large samples of recombinant bacterial whole genome sequences
using Gubbins. Nucleic Acids Res. 2015;43(3):e15.

67. Bolger AM, Lohse M, Usadel B. Trimmomatic: A flexible trimmer for Illumina sequence data.
Bioinforma Oxf Engl. 2014;30(15):2114–20.

68. Inouye M, Dashnow H, Raven LA, Schultz MB, Pope BJ, Tomita T, et al. SRST2: Rapid
genomic surveillance for public health and hospital microbiology labs. Genome Med.
2014;6(90):1–16.

69. Jolley KA, Bray JE, Maiden MCJ. Open-access bacterial population genomics: BIGSdb
software, the PubMLST.org website and their applications. Wellcome Open Res. 2018;3.

70. Page AJ, Taylor B, Delaney AJ, Soares J, Seemann T, Keane JA, et al. SNP-sites: Rapid
efficient extraction of SNPs from multi-FASTA alignments. Microb Genomics.
2016;2(4):e000056.

71. Minh BQ, Schmidt HA, Chernomor O, Schrempf D, Woodhams MD, von Haeseler A, et al.
IQ-TREE 2: New Models and Efficient Methods for Phylogenetic Inference in the Genomic
Era. Mol Biol Evol. 2020;37(5):1530–4.

72. Hoang DT, Chernomor O, von Haeseler A, Minh BQ, Vinh LS. UFBoot2: Improving the
Ultrafast Bootstrap Approximation. Mol Biol Evol. 2018;35(2):518–22.

73. Kalyaanamoorthy S, Minh BQ, Wong TKF, von Haeseler A, Jermiin LS. ModelFinder: fast
model selection for accurate phylogenetic estimates. Nat Methods. 2017;14(6):587–9.

74. Letunic I, Bork P. Interactive Tree Of Life (iTOL) v5: an online tool for phylogenetic tree
display and annotation. Nucleic Acids Res. 2021;49(W1):W293–6.

75. Wick RR, Judd LM, Gorrie CL, Holt KE. Unicycler: Resolving bacterial genome assemblies
from short and long sequencing reads. PLoS Comput Biol. 2017;13(6):e1005595.

76. Ronquist F, Teslenko M, van der Mark P, Ayres DL, Darling A, Höhna S, et al. MrBayes 3.2:
Efficient Bayesian Phylogenetic Inference and Model Choice Across a Large Model Space.
Syst Biol. 2012;61(3):539–42.

77. Wymant C, Hall M, Ratmann O, Bonsall D, Golubchik T, de Cesare M, et al.
PHYLOSCANNER: Inferring Transmission from Within- and Between-Host Pathogen
Genetic Diversity. Mol Biol Evol. 2018;35(3):719–33.

78. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: A
Software Environment for Integrated Models of Biomolecular Interaction Networks. Genome
Res. 2003;13(11):2498–504.

79. Huebner RE, Dagan R, Porath N, Wasas AD, T M, Klugman KP. Lack of Utility of
Serotyping Multiple Colonies for Detection of Simultaneous Nasopharyngeal Carriage of
Differnt Pneumococcal Serotypes. Pediatr Infect Dis J. 2000;19(10):1017–20.

80. R Core Team. R: A Language and Environment for Statistical Computing [Internet]. Vienna,
Austria: R Foundation for Statistical Computing; 2021. Available from: https://www.R-
project.org/

81. Wickham H. ggplot2: Elegant Graphics for Data Analysis [Internet]. Springer-Verlag New
York; 2016. Available from: https://ggplot2.tidyverse.org

82. Pedersen TL. patchwork: The Composer of Plots [Internet]. 2020. Available from:
https://CRAN.R-project.org/package=patchwork

737
738
739
740

742   **Table 1** – Characteristics of patients with rectal VREfm colonisation (n = 13)

Demographics	N (%)
Female	8 (61.5)
Age, median (range) years	66 (37-77)
Primary diagnosis	
Acute myeloid leukaemia	3 (23.1)
Diffuse large B cell lymphoma	3 (23.1)
Multiple myeloma	3 (23.1)
Myelodysplasia	2 (15.4)
Chronic lymphocytic leukaemia	1 (7.7)
Mantle cell lymphoma	1 (7.7)
Antimicrobial administration	
Any antibiotics in the 7d prior to positive screen	12 (92.3)
Any antibiotics in the 6m prior to positive screen	12 (92.3)
Vancomycin in the 7d prior to positive screen	1 (7.7)
Vancomycin in the 6m prior to positive screen[a]	3 (30.0)
Outcomes within 60d of VREfm positive screen	
VREfm bloodstream infection	3 (23.1)
ICU admission	1 (7.7)
Death	0 (0)

743   [a] Information available for 10 patients

Table 2 – MLST Sequence Types Detected

Patient ID	Sample ID	Sample Type	Sample Date (days from start of study)	STs detected (n, %)	Maximum pairwise SNP distance within sample	Median (IQR) pairwise SNP distance within sample
P2	VRED01	Rectal	6	80 (14, 100)	2	0 (0 - 1)
P6	VRED16	Rectal	27	1424 (14, 100)	2	0 (0 - 1)
P7	VRED10	Rectal	18	80 (14, 100)	3	0 (0 - 1)
P9	VRED02	Rectal	6	80 (14, 100)	1	0 (0 - 0)
P9	VRED03	Rectal	8	80 (14, 100)	0	0 (0 - 0)
P9	VRED09	Rectal	17	80 (14, 100)	1	0 (0 - 0)
P9	VRED18	Blood	52	80 (1, 100)	NA	NA
P9	VRED19	Blood	52	80 (1, 100)	NA	NA
P9	VRED20	Blood	52	80 (1, 100)	NA	NA
P9	VRED21	Blood	52	80 (1, 100)	NA	NA
P14	VRED07	Rectal	17	1424 (10, 71.4); 80 (4, 26.6)	491	2 (1 - 482)
P20	VRED15	Rectal	27	80 (14, 100)	3	1 (0 - 2)
P20	VRED17	Rectal	30	80 (14, 100)	3	1 (0 - 1)
P24	VRED13	Rectal	26	1424 (14, 100)	2	0 (0 - 0)
P33	VRED12	Rectal	24	80 (14, 100)	2	0 (0 - 1)
P34	VRED04	Rectal	9	1424 (14, 100)	1	0 (0 - 0)
P34	VRED05	Rectal	14	1424 (14, 100)	4	0 (0 - 1)
P49	VRED06	Rectal	15	80 (10, 71.4); 1424 (3, 21.4); 789 (1, 7.1)	490	0 (0 - 482)
P49	VRED08	Rectal	17	1424 (14, 100)	2	0 (0 - 1)
P49	VRED14	Blood	30	1424 (1, 100)	NA	NA
P50	VRED11	Rectal	23	1424 (13, 92.9); 1659 (1, 7.1)	4429	1 (0 - 2)

748 **Table 3** – Presence of AMR Genes

Gene	Phenotypic resistance	ST80, n = 130		ST1424, n = 97		All Isolates, n = 229	
		n (%)	Genetic element	n (%)	Genetic element	n (%)	Summary
aac(6')-aph(2'')	Amikacin, Gentamicin, Kanamycin, Streptomycin, Tobramycin	65 (50.0)	p1_VRED06-10	94 (96.9)	p1_VRED06-02	160 (69.9)	Variable in ST80/ST1424/ST789
aac(6')-Ii	Gentamicin, Tobramycin	130 (100)	Chromosome	97 (100)	Chromosome	229 (100)	All isolates
ant(6)-Ia	Streptomycin	130 (100)	p3_VRED06-10	0 (0)	NA	131 (57.2)	All ST80/ST789
ant(9)-Ia	Spectinomycin	0 (0)	NA	97 (100)	Chromosome	97 (42.4)	All ST1424
aph(3')-III	Amikacin, Kanamycin, Neomycin	130 (100)	p3_VRED06-10	97 (100)	p2_VRED06-02	228 (99.6)	All ST80/ST789/ST1424
dfrG	Trimethoprim	0 (0)	NA	97 (100)	Chromosome	97 (42.4)	All ST1424
erm(A)	Clindamycin, Erythromycin, Quinupristin	0 (0)	NA	97 (100)	Chromosome	97 (42.4)	All ST1424
erm(B)	Clindamycin, Erythromycin, Quinupristin	129 (99.2)	p1_VRED06-10, p3_VRED06-10	97 (100)	p2_VRED06-02	228 (99.6)	All except one ST80 isolate
msr(C)	Erythromycin, Quinupristin	130 (100)	Chromosome	97 (100)	Chromosome	229 (100)	All isolates
tet(L)	Doxycycline, Tetracycline	0 (0)	NA	0 (0)	NA	1 (0.4)	Only ST1659
tet(M)	Doxycycline, Minocycline, Tetracycline	0 (0)	NA	60 (61.9)	Chromosome	61 (26.6)	Variable in ST1424/ST1659
tet(S)	Doxycycline, Minocycline, Tetracycline	130 (100)	p3_VRED06-10	0 (0)	NA	131 (57.2)	All ST80/ST789
VanA	Teicoplanin, Vancomycin	97 (100)	p2_VRED06-02	97 (100)	p2_VRED06-02	229 (100)	All isolates

749
750

Figure 1 – Patient timeline. Each row denotes the location of a patient during admission, blocks denote hospital stay, circles denote VREfm cultures, stars denote bloodstream isolates, dotted lines indicate the start and end of prospective collection of screening isolates for this study. This study was undertaken mainly within Wards A and B, although patients were moved to different wards within the hospital during their stay and were often admitted through the assessment unit.

Figure 2 – Phylogeny of ST80 isolates showing structured population with three patient specific

clusters and two clusters indicating putative patient-patient transmission of VREfm. All ST80

isolates mapped to VRED06-10 chromosome and phylogeny built on SNP sites (n=96) after

removal of putative transposable and recombinant regions.

Figure 3 – Phylogeny of ST1424 isolates showing homogeneous population suggestive of

recent transmission outbreak. ST1424 isolates (n=98) mapped to VRED06-02 chromosome and

phylogeny built on SNP sites (n=13) after removal of putative transposable and recombinant

regions.

773 **Figure 4** – Phyloscanner transmission network. Each patient is represented by a node coloured

774 by detection of the two outbreak STs. Edge thickness corresponds to fraction of Phyloscanner

775 trees with given relationship, relationship fraction is printed alongside each edge, and edge

776 colour based on type of relationship (orange, direct transmission; blue, transmission but

777 direction unclear).

Figure 5 – Detection of antimicrobial resistance genes. Panels represent different patients;

resistance genes are plotted on the y-axis and isolates on the x-axis. Presence of a gene is

represented by a filled square and coloured based on the MLST ST of the isolate.